{
  "schemaVersion": 1,
  "organisationId": "O-11f8f750fe3f4bbdb6171bd4e03a064d",
  "slug": "sandoz-group",
  "name": "SANDOZ GROUP",
  "updatedAt": "2026-03-20T06:41:39.593184Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Sandoz Group is a global pharmaceutical company focused on generic medicines and biosimilars. The company describes itself as a uniquely global generics and biosimilars producer and frames its business around affordable healthcare, supplying around 1,300 products and operating in more than 100 countries, with a leading presence across its three regions. [P-b7b7ab76c2ee48eaaadb2f75b5cb3df3][P-a2f48a9b8937462a8a270c7c179275a4][P-98061040ad07417d97443bc772ef872b][P-c8090224c69d40a09c561e2d51142f5a]\n\nSandoz states that its purpose is “pioneering access for patients,” and its vision is to be the world’s leading and most valued generics and biosimilars company. As a scale indicator, it reported 2024 net sales to third parties of USD 10.4 billion and employed around 23,000 people worldwide; in 2024 it delivered more than 900 million patient treatments. [P-79a9748263024e67a2bc59005d570420][P-907cf4ee081b48ea9ede724a1041a01c][P-8cce7c1b95674eaaa71ca9701187c75f][P-b94beb8e93e544f8bf3c6ca27a959e0e][P-98061040ad07417d97443bc772ef872b][P-2294f648b7e14fb59942ec013bd92011]\n[P-b7b7ab76c2ee48eaaadb2f75b5cb3df3][P-a2f48a9b8937462a8a270c7c179275a4][P-98061040ad07417d97443bc772ef872b][P-c8090224c69d40a09c561e2d51142f5a][P-79a9748263024e67a2bc59005d570420][P-907cf4ee081b48ea9ede724a1041a01c][P-8cce7c1b95674eaaa71ca9701187c75f][P-b94beb8e93e544f8bf3c6ca27a959e0e][P-2294f648b7e14fb59942ec013bd92011]",
      "updatedAt": "2026-03-20T06:41:39.593184Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Sandoz’s product portfolio comprises approximately 1,500 products across generics and biosimilars, with generics accounting for 72% of 2024 net sales and biosimilars 28%; biosimilar sales were about USD 2.9 billion in 2024.[P-bda574c918194b2a87d55249c7726795][P-0103fa015d0342f19c10a827d6e3beee][P-6d9343a7bdb54779a66245b08f6f7761] Its generics portfolio covers cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory medicines, and includes a leading generic antibiotics franchise with 50-plus medicines serving several hundred million patients per year.[P-02357921b26842008b0a77b9865556fa][P-b2dbcc78644f4aa28cfa83d648b4ecb4] Technically, Sandoz develops standard generics that are primarily oral solids as well as complex generics such as injectables and respiratory inhalers, plus liquids, sprays, topicals and transdermal patches; it also cites development expertise in emerging areas such as oligonucleotides and long-acting injectables.[P-b57908593e5c46d988b31ea0e1e4253e]\n\nIts biosimilar portfolio includes Omnitrope (somatropin), described as the world’s first biosimilar; oncology supportive-care products Binocrit (epoetin alfa), Zarzio/Zarxio (filgrastim) and Ziextenzo (pegfilgrastim); immunology products Erelzi (etanercept), Hyrimoz (adalimumab), Zessly (infliximab) and Pyzchiva (ustekinumab); Rixathon (rituximab) for blood cancers and rheumatology; Cimerli (ranibizumab) for multiple retinal diseases; Tyruko (natalizumab), described as the first and only approved biosimilar for multiple sclerosis; and Wyost and Jubbonti (denosumab) for oncology and osteoporosis.[P-c36f5f6a68d2402a974cfa0ae0aad5c2][P-2fe77c2074c246f6966e40f5539822a5][P-95b74d4cab12430eb72393af3b1e3e53][P-96758c211050495faebc1f6a0524c98f][P-d6cdf0e0d29e4b66b8cd3e2ff6fdc75b][P-dec57f8f6a1146d5bf70932589e5dba2][P-4508bc53e59043a0840d9693d34bfe97][P-c2679093022e41a1abd698756a929b0d][P-c6c85a3d0a024ef6b98f47f83038cda6][P-ec9ca584c0e447c6965fcdde11b80eac][P-468d06a9c2064e6c9753d1e5763d24ae][P-26102a0b84374176b3ed9026b8e29339][P-6ef0cf1f53ae410faf7d7da81adbc532][P-cd684abd80d14c628cf965d42378ad9e] Hyrimoz is specifically offered in both low- and high-concentration formulations.[P-dec57f8f6a1146d5bf70932589e5dba2]\n\nRelated service offerings include patient support services for some US-marketed products focused on access, affordability and adherence, including copay support and nurse-administered injection training.[P-36e1cc0616304509b37e3b118dfb3b31] In ophthalmology, the Cimerli business also included a dedicated retina sales and field reimbursement team.[P-ec9ca584c0e447c6965fcdde11b80eac]\n[P-bda574c918194b2a87d55249c7726795][P-0103fa015d0342f19c10a827d6e3beee][P-6d9343a7bdb54779a66245b08f6f7761][P-02357921b26842008b0a77b9865556fa][P-b2dbcc78644f4aa28cfa83d648b4ecb4][P-b57908593e5c46d988b31ea0e1e4253e][P-c36f5f6a68d2402a974cfa0ae0aad5c2][P-2fe77c2074c246f6966e40f5539822a5][P-95b74d4cab12430eb72393af3b1e3e53][P-96758c211050495faebc1f6a0524c98f][P-d6cdf0e0d29e4b66b8cd3e2ff6fdc75b][P-dec57f8f6a1146d5bf70932589e5dba2][P-4508bc53e59043a0840d9693d34bfe97][P-c2679093022e41a1abd698756a929b0d][P-c6c85a3d0a024ef6b98f47f83038cda6][P-ec9ca584c0e447c6965fcdde11b80eac][P-468d06a9c2064e6c9753d1e5763d24ae][P-26102a0b84374176b3ed9026b8e29339][P-6ef0cf1f53ae410faf7d7da81adbc532][P-cd684abd80d14c628cf965d42378ad9e][P-36e1cc0616304509b37e3b118dfb3b31]",
      "updatedAt": "2026-03-20T06:41:39.593184Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Sandoz’s 2024 net sales to third parties were geographically split across Europe (USD 5.4 billion, 52%), North America (USD 2.4 billion, 23%), and International (USD 2.6 billion, 25%), making Europe its largest sales region.[P-c25241c22839451a936a04e10a2bf687][P-99f148ec2e0f4dda81d007b3ed9b4bc8][P-efa83a3fcecf46928feca0d4de12116f] By customer location, the United States represented 18% of net sales, Germany 13%, Switzerland 4%, and all other countries 65%.[P-2a830b200ae340fe877ac468492b73db][T-e6ead1ca1fed4c24833f801d68c02bb0][P-fe294cb7f1bc45a293837802683f862f]\n\nThe group is domiciled in Risch, Switzerland, and Sandoz AG lists an address in Basel, Switzerland.[P-eb113c9d77a64543a4167eace057abcc][P-3ae43a8df9b04c8ca7b12519ca563057] Sandoz says it supports 100+ countries with roughly 23,000 employees and operates a manufacturing and supply network of 15 Sandoz-owned sites plus 700+ external sites.[P-254ef7d715d741f2b5d8d37a4ebd6144][P-98061040ad07417d97443bc772ef872b][P-508400e43b0c4bcd88b7c7c4e3604559][P-c8ddb172d1ba45cca1eeea216714e9c0] Within the International region, Sandoz says it is directly present in over 20 markets and serves another 30 through a distribution model, and it highlights Kundl, Austria, as the only major remaining fully integrated supplier of antibiotics in Europe.[P-aa402d1b9194444caa8de151dd67693a][P-0225cddce0534bdea9f70cf816a3c8d9]\n[P-c25241c22839451a936a04e10a2bf687][P-99f148ec2e0f4dda81d007b3ed9b4bc8][P-efa83a3fcecf46928feca0d4de12116f][P-2a830b200ae340fe877ac468492b73db][T-e6ead1ca1fed4c24833f801d68c02bb0][P-fe294cb7f1bc45a293837802683f862f][P-eb113c9d77a64543a4167eace057abcc][P-3ae43a8df9b04c8ca7b12519ca563057][P-254ef7d715d741f2b5d8d37a4ebd6144][P-98061040ad07417d97443bc772ef872b][P-508400e43b0c4bcd88b7c7c4e3604559][P-c8ddb172d1ba45cca1eeea216714e9c0][P-aa402d1b9194444caa8de151dd67693a][P-0225cddce0534bdea9f70cf816a3c8d9]",
      "updatedAt": "2026-03-20T06:41:39.593184Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Sandoz officially reports itself as a single operating segment engaged in the development, manufacturing and marketing of generic and biosimilar medicines, rather than as separate operating segments.[P-86f8aa8908d44d4c8e583429962e99d9] For additional business-level disclosure, it breaks out net sales between Generics and Biosimilars.[P-0103fa015d0342f19c10a827d6e3beee] Generics are described as off-patent medicines with the same safety, efficacy and quality as originator medicines, while biosimilars are biologic medicines made using biological production technologies to the same quality standards as their reference biologics and intended to expand access to biologic treatment.[P-00641c51e6124e5996111085d1f74555][P-b4a2a7f50c7d4bf0bebcefa7dc21cf8e][P-b0c38eaa97004919854dd69e66cc63d9] In 2024, Generics contributed USD 7,504 million of net sales, or about 72% of the total, and Biosimilars contributed USD 2,853 million, or about 28%.[P-0103fa015d0342f19c10a827d6e3beee]\n\nSandoz also discloses revenue by geography, splitting sales into Europe, North America and International.[P-289e80fdc94e42bb9c519d1f7d193929] In 2024, Europe contributed USD 5,363 million (about 52% of net sales), North America USD 2,437 million (about 24%), and International USD 2,557 million (about 25%).[P-289e80fdc94e42bb9c519d1f7d193929] The same disclosure shows the regional mix by business: Europe comprised USD 3,769 million of Generics and USD 1,594 million of Biosimilars; North America USD 1,622 million of Generics and USD 815 million of Biosimilars; and International USD 2,113 million of Generics and USD 444 million of Biosimilars, implying biosimilars are relatively more important in Europe and North America than in the International region.[P-289e80fdc94e42bb9c519d1f7d193929]\n[P-86f8aa8908d44d4c8e583429962e99d9][P-00641c51e6124e5996111085d1f74555][P-b4a2a7f50c7d4bf0bebcefa7dc21cf8e][P-b0c38eaa97004919854dd69e66cc63d9][P-0103fa015d0342f19c10a827d6e3beee][P-289e80fdc94e42bb9c519d1f7d193929]",
      "updatedAt": "2026-03-20T06:41:39.593184Z"
    },
    {
      "type": "HISTORY",
      "text": "Sandoz traces its origins to 1886, when Alfred Kern and Edouard Sandoz founded Kern & Sandoz in Basel, Switzerland.[P-a1ff6d9d0ce54dcbaa112b9e8759fd6d][P-0a712605138346fd81c472857e30a33d] In its early decades, the company developed products such as Calcium Sandoz in 1929, and in 1951 it achieved a major pharmaceutical milestone with what it describes as the world’s first oral penicillin, helped by work at its Kundl, Austria site.[P-18e52343d5804030876b629d7604bd00][P-b929813476364e00af9e44614fff3169]\n\nA major corporate turning point came in 1996, when Sandoz merged with Ciba-Geigy to form Novartis, after which the Sandoz name was later re-established as the umbrella brand for Novartis’s off-patent medicines business.[P-beef19189e1f4215b447c4c9330e19e3] In 2006, Sandoz launched Omnitrope, which it identifies as the world’s first biosimilar, marking another important step in its development.[P-c36f5f6a68d2402a974cfa0ae0aad5c2][P-18e52343d5804030876b629d7604bd00] On 4 October 2023, Sandoz again became a standalone company when it was spun off from Novartis and listed as an independent publicly traded business.[P-352f693b655941b4b340add1509dde0a]\n[P-a1ff6d9d0ce54dcbaa112b9e8759fd6d][P-0a712605138346fd81c472857e30a33d][P-18e52343d5804030876b629d7604bd00][P-b929813476364e00af9e44614fff3169][P-beef19189e1f4215b447c4c9330e19e3][P-c36f5f6a68d2402a974cfa0ae0aad5c2][P-352f693b655941b4b340add1509dde0a]",
      "updatedAt": "2026-03-20T06:41:39.593184Z"
    }
  ],
  "sources": [
    {
      "id": "P-b7b7ab76c2ee48eaaadb2f75b5cb3df3",
      "href": "https://app.finbar.com/go?id=P-b7b7ab76c2ee48eaaadb2f75b5cb3df3",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p9",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 9
    },
    {
      "id": "P-a2f48a9b8937462a8a270c7c179275a4",
      "href": "https://app.finbar.com/go?id=P-a2f48a9b8937462a8a270c7c179275a4",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p5",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 5
    },
    {
      "id": "P-98061040ad07417d97443bc772ef872b",
      "href": "https://app.finbar.com/go?id=P-98061040ad07417d97443bc772ef872b",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p7",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 7
    },
    {
      "id": "P-c8090224c69d40a09c561e2d51142f5a",
      "href": "https://app.finbar.com/go?id=P-c8090224c69d40a09c561e2d51142f5a",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p7",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 7
    },
    {
      "id": "P-79a9748263024e67a2bc59005d570420",
      "href": "https://app.finbar.com/go?id=P-79a9748263024e67a2bc59005d570420",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p6",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 6
    },
    {
      "id": "P-907cf4ee081b48ea9ede724a1041a01c",
      "href": "https://app.finbar.com/go?id=P-907cf4ee081b48ea9ede724a1041a01c",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p6",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 6
    },
    {
      "id": "P-8cce7c1b95674eaaa71ca9701187c75f",
      "href": "https://app.finbar.com/go?id=P-8cce7c1b95674eaaa71ca9701187c75f",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p3",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 3
    },
    {
      "id": "P-b94beb8e93e544f8bf3c6ca27a959e0e",
      "href": "https://app.finbar.com/go?id=P-b94beb8e93e544f8bf3c6ca27a959e0e",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p3",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 3
    },
    {
      "id": "P-2294f648b7e14fb59942ec013bd92011",
      "href": "https://app.finbar.com/go?id=P-2294f648b7e14fb59942ec013bd92011",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p6",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 6
    },
    {
      "id": "P-bda574c918194b2a87d55249c7726795",
      "href": "https://app.finbar.com/go?id=P-bda574c918194b2a87d55249c7726795",
      "label": "SANDOZ GROUP — Full financial report (2023 Y), p29",
      "documentId": "D-b048c6d0d9a24d4da90fac4c93e72730",
      "page": 29
    },
    {
      "id": "P-0103fa015d0342f19c10a827d6e3beee",
      "href": "https://app.finbar.com/go?id=P-0103fa015d0342f19c10a827d6e3beee",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p96",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 96
    },
    {
      "id": "P-6d9343a7bdb54779a66245b08f6f7761",
      "href": "https://app.finbar.com/go?id=P-6d9343a7bdb54779a66245b08f6f7761",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p96",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 96
    },
    {
      "id": "P-02357921b26842008b0a77b9865556fa",
      "href": "https://app.finbar.com/go?id=P-02357921b26842008b0a77b9865556fa",
      "label": "SANDOZ GROUP — Full financial report (2023 Y), p29",
      "documentId": "D-b048c6d0d9a24d4da90fac4c93e72730",
      "page": 29
    },
    {
      "id": "P-b2dbcc78644f4aa28cfa83d648b4ecb4",
      "href": "https://app.finbar.com/go?id=P-b2dbcc78644f4aa28cfa83d648b4ecb4",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p7",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 7
    },
    {
      "id": "P-b57908593e5c46d988b31ea0e1e4253e",
      "href": "https://app.finbar.com/go?id=P-b57908593e5c46d988b31ea0e1e4253e",
      "label": "SANDOZ GROUP — Full financial report (2023 Y), p29",
      "documentId": "D-b048c6d0d9a24d4da90fac4c93e72730",
      "page": 29
    },
    {
      "id": "P-c36f5f6a68d2402a974cfa0ae0aad5c2",
      "href": "https://app.finbar.com/go?id=P-c36f5f6a68d2402a974cfa0ae0aad5c2",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p19",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 19
    },
    {
      "id": "P-2fe77c2074c246f6966e40f5539822a5",
      "href": "https://app.finbar.com/go?id=P-2fe77c2074c246f6966e40f5539822a5",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-95b74d4cab12430eb72393af3b1e3e53",
      "href": "https://app.finbar.com/go?id=P-95b74d4cab12430eb72393af3b1e3e53",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-96758c211050495faebc1f6a0524c98f",
      "href": "https://app.finbar.com/go?id=P-96758c211050495faebc1f6a0524c98f",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-d6cdf0e0d29e4b66b8cd3e2ff6fdc75b",
      "href": "https://app.finbar.com/go?id=P-d6cdf0e0d29e4b66b8cd3e2ff6fdc75b",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-dec57f8f6a1146d5bf70932589e5dba2",
      "href": "https://app.finbar.com/go?id=P-dec57f8f6a1146d5bf70932589e5dba2",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-4508bc53e59043a0840d9693d34bfe97",
      "href": "https://app.finbar.com/go?id=P-4508bc53e59043a0840d9693d34bfe97",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-c2679093022e41a1abd698756a929b0d",
      "href": "https://app.finbar.com/go?id=P-c2679093022e41a1abd698756a929b0d",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-c6c85a3d0a024ef6b98f47f83038cda6",
      "href": "https://app.finbar.com/go?id=P-c6c85a3d0a024ef6b98f47f83038cda6",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-ec9ca584c0e447c6965fcdde11b80eac",
      "href": "https://app.finbar.com/go?id=P-ec9ca584c0e447c6965fcdde11b80eac",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-468d06a9c2064e6c9753d1e5763d24ae",
      "href": "https://app.finbar.com/go?id=P-468d06a9c2064e6c9753d1e5763d24ae",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-26102a0b84374176b3ed9026b8e29339",
      "href": "https://app.finbar.com/go?id=P-26102a0b84374176b3ed9026b8e29339",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-6ef0cf1f53ae410faf7d7da81adbc532",
      "href": "https://app.finbar.com/go?id=P-6ef0cf1f53ae410faf7d7da81adbc532",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-cd684abd80d14c628cf965d42378ad9e",
      "href": "https://app.finbar.com/go?id=P-cd684abd80d14c628cf965d42378ad9e",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p22",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 22
    },
    {
      "id": "P-36e1cc0616304509b37e3b118dfb3b31",
      "href": "https://app.finbar.com/go?id=P-36e1cc0616304509b37e3b118dfb3b31",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p27",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 27
    },
    {
      "id": "P-c25241c22839451a936a04e10a2bf687",
      "href": "https://app.finbar.com/go?id=P-c25241c22839451a936a04e10a2bf687",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p7",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 7
    },
    {
      "id": "P-99f148ec2e0f4dda81d007b3ed9b4bc8",
      "href": "https://app.finbar.com/go?id=P-99f148ec2e0f4dda81d007b3ed9b4bc8",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p7",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 7
    },
    {
      "id": "P-efa83a3fcecf46928feca0d4de12116f",
      "href": "https://app.finbar.com/go?id=P-efa83a3fcecf46928feca0d4de12116f",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p7",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 7
    },
    {
      "id": "P-2a830b200ae340fe877ac468492b73db",
      "href": "https://app.finbar.com/go?id=P-2a830b200ae340fe877ac468492b73db",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p116",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 116
    },
    {
      "id": "T-e6ead1ca1fed4c24833f801d68c02bb0",
      "href": "https://app.finbar.com/go?id=T-e6ead1ca1fed4c24833f801d68c02bb0",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p116",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 116
    },
    {
      "id": "P-fe294cb7f1bc45a293837802683f862f",
      "href": "https://app.finbar.com/go?id=P-fe294cb7f1bc45a293837802683f862f",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p116",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 116
    },
    {
      "id": "P-eb113c9d77a64543a4167eace057abcc",
      "href": "https://app.finbar.com/go?id=P-eb113c9d77a64543a4167eace057abcc",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p107",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 107
    },
    {
      "id": "P-3ae43a8df9b04c8ca7b12519ca563057",
      "href": "https://app.finbar.com/go?id=P-3ae43a8df9b04c8ca7b12519ca563057",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p189",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 189
    },
    {
      "id": "P-254ef7d715d741f2b5d8d37a4ebd6144",
      "href": "https://app.finbar.com/go?id=P-254ef7d715d741f2b5d8d37a4ebd6144",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p40",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 40
    },
    {
      "id": "P-508400e43b0c4bcd88b7c7c4e3604559",
      "href": "https://app.finbar.com/go?id=P-508400e43b0c4bcd88b7c7c4e3604559",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p8",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 8
    },
    {
      "id": "P-c8ddb172d1ba45cca1eeea216714e9c0",
      "href": "https://app.finbar.com/go?id=P-c8ddb172d1ba45cca1eeea216714e9c0",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p8",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 8
    },
    {
      "id": "P-aa402d1b9194444caa8de151dd67693a",
      "href": "https://app.finbar.com/go?id=P-aa402d1b9194444caa8de151dd67693a",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p28",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 28
    },
    {
      "id": "P-0225cddce0534bdea9f70cf816a3c8d9",
      "href": "https://app.finbar.com/go?id=P-0225cddce0534bdea9f70cf816a3c8d9",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p14",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 14
    },
    {
      "id": "P-86f8aa8908d44d4c8e583429962e99d9",
      "href": "https://app.finbar.com/go?id=P-86f8aa8908d44d4c8e583429962e99d9",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p116",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 116
    },
    {
      "id": "P-00641c51e6124e5996111085d1f74555",
      "href": "https://app.finbar.com/go?id=P-00641c51e6124e5996111085d1f74555",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p17",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 17
    },
    {
      "id": "P-b4a2a7f50c7d4bf0bebcefa7dc21cf8e",
      "href": "https://app.finbar.com/go?id=P-b4a2a7f50c7d4bf0bebcefa7dc21cf8e",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p20",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 20
    },
    {
      "id": "P-b0c38eaa97004919854dd69e66cc63d9",
      "href": "https://app.finbar.com/go?id=P-b0c38eaa97004919854dd69e66cc63d9",
      "label": "SANDOZ GROUP — Full financial report (2024 Y), p20",
      "documentId": "D-9a1e7035a8e64cd0afacc7246d877f9e",
      "page": 20
    },
    {
      "id": "P-289e80fdc94e42bb9c519d1f7d193929",
      "href": "https://app.finbar.com/go?id=P-289e80fdc94e42bb9c519d1f7d193929",
      "label": "SANDOZ GROUP — Presentation (2024 Y), p8",
      "documentId": "D-201b9ea5b49540308f3b3f1e3ed1060d",
      "page": 8
    },
    {
      "id": "P-a1ff6d9d0ce54dcbaa112b9e8759fd6d",
      "href": "https://app.finbar.com/go?id=P-a1ff6d9d0ce54dcbaa112b9e8759fd6d",
      "label": "SANDOZ GROUP — Full financial report (2023 Y), p18",
      "documentId": "D-b048c6d0d9a24d4da90fac4c93e72730",
      "page": 18
    },
    {
      "id": "P-0a712605138346fd81c472857e30a33d",
      "href": "https://app.finbar.com/go?id=P-0a712605138346fd81c472857e30a33d",
      "label": "SANDOZ GROUP — Full financial report (2025 Y), p9",
      "documentId": "D-a09394b8ddd54a2b8285bd53e5f52256",
      "page": 9
    },
    {
      "id": "P-18e52343d5804030876b629d7604bd00",
      "href": "https://app.finbar.com/go?id=P-18e52343d5804030876b629d7604bd00",
      "label": "SANDOZ GROUP — Press release (2024 Q 3), p4",
      "documentId": "D-7d71db393ab74bcca5b17afc83d35566",
      "page": 4
    },
    {
      "id": "P-b929813476364e00af9e44614fff3169",
      "href": "https://app.finbar.com/go?id=P-b929813476364e00af9e44614fff3169",
      "label": "SANDOZ GROUP — Full financial report (2025 Y), p9",
      "documentId": "D-a09394b8ddd54a2b8285bd53e5f52256",
      "page": 9
    },
    {
      "id": "P-beef19189e1f4215b447c4c9330e19e3",
      "href": "https://app.finbar.com/go?id=P-beef19189e1f4215b447c4c9330e19e3",
      "label": "SANDOZ GROUP — Full financial report (2023 Y), p74",
      "documentId": "D-b048c6d0d9a24d4da90fac4c93e72730",
      "page": 74
    },
    {
      "id": "P-352f693b655941b4b340add1509dde0a",
      "href": "https://app.finbar.com/go?id=P-352f693b655941b4b340add1509dde0a",
      "label": "SANDOZ GROUP — Full financial report (2023 Y), p200",
      "documentId": "D-b048c6d0d9a24d4da90fac4c93e72730",
      "page": 200
    }
  ]
}